- No evidence of residual involved lymph node disease or metastatic disease at the time of registration based on clinician assessment of imaging. The treating physician will determine if incidental lesions on imaging require workup to exclude metastatic disease. If based on review of images, the treating physician determines the patient to be stage III, then the patient is eligible
|
-
No prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for colon cancer except for one cycle of mFOLFOX6
|
-
No active known autoimmune disease, including colitis, inflammatory bowel disease (i.e. ulcerative colitis or Crohn's disease), rheumatoid arthritis, panhypopituitarism, adrenal insufficiency
|
-
No known active hepatitis B or C
|
-
No other planned concurrent investigational agents or other tumor directed therapy (chemotherapy, radiation) while on study
|
-
No systemic daily treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of registration
|
-
No known history of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins
|
-
No known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the atezolizumab formulation
|
-
No known allergy to 5-fluorouracil, oxaliplatin, or leucovorin
|
-
Contact site personnel for more study details
|